Evidence map›Paper›PMID 42162317›Full record

ArticleNature cancer2026

Coupling dead cell recognition to Fcγ receptors augments anticancer immunity.

Tomás Castro-Dopico, Cécile Piot, Michael D Buck, Lucía Gandullo-Sánchez, Kok Haw Jonathan Lim, Gerone A Gonzales, Nikita Rosendahl, Oliver Schulz, William Stainier, Brian Vash and 17 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Tomás Castro-DopicoImmunobiology Laboratory, The Francis Crick Institute, London, UK. tomas.castro-dopico@crick.ac.uk.ORCID http://orcid.org/0000-0002-6964-5478
Cécile Piot *Immunobiology Laboratory, The Francis Crick Institute, London, UK.
Michael D Buck *Immunobiology Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0002-9611-1199
Lucía Gandullo-Sánchez *Immunobiology Laboratory, The Francis Crick Institute, London, UK.
Kok Haw Jonathan LimImmunobiology Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0002-6544-9218
Gerone A GonzalesFaculty of Veterinary Medicine, University of Calgary, Calgary, Alberta, Canada.
Nikita RosendahlMater Research Institute, The University of Queensland, Translational Research Institute, Brisbane, Queensland, Australia.ORCID http://orcid.org/0000-0002-5188-7487
Oliver SchulzImmunobiology Laboratory, The Francis Crick Institute, London, UK.
William StainierImmunobiology Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0009-0003-6182-4003
Brian VashApple Tree Partners, Cambridge, MA, USA.
Stephanie MaioccoApple Tree Partners, Cambridge, MA, USA.
Conor M HenryImmunobiology Laboratory, The Francis Crick Institute, London, UK.
Bruno FredericoImmunobiology Laboratory, The Francis Crick Institute, London, UK.
Sonia LeeImmunobiology Laboratory, The Francis Crick Institute, London, UK.
Andy Bo ZhangImmunobiology Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0002-4672-4181
Neil C RogersImmunobiology Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0001-8977-7585
Jayanta BordoloiIn vivo Imaging, The Francis Crick Institute, London, UK.
Chloë RoustanStructural Biology, The Francis Crick Institute, London, UK.
Svend KjaerStructural Biology, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0001-9767-8683
Mohit TrikhaDrug Design Corp., San Francisco, CA, USA.
Hans StaussInstitute of Immunology & Transplantation, University College London, London, UK.ORCID http://orcid.org/0000-0003-4340-7911
Ahmet HaziniDepartment of Oncology, University of Oxford, Oxford, UK.
Kristen J RadfordMater Research Institute, The University of Queensland, Translational Research Institute, Brisbane, Queensland, Australia.ORCID http://orcid.org/0000-0001-6512-6323
Zewen Kelvin TuongIan Frazer Centre for Children's Immunotherapy Research, Child Health Research Centre, Faculty of Health, Medicine and Behavioural Sciences, The University of Queensland, Brisbane, Queensland, Australia.ORCID http://orcid.org/0000-0002-6735-6808
Johnathan CantonFaculty of Veterinary Medicine, University of Calgary, Calgary, Alberta, Canada.
Raj MehtaAdendra Therapeutics Ltd, London, UK.
Caetano Reis E SousaImmunobiology Laboratory, The Francis Crick Institute, London, UK. caetano@crick.ac.uk.ORCID http://orcid.org/0000-0001-7392-2119

Funding

Cancer Research UK (CRUK) CC2090EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 Marie Skłodowska-Curie Actions (H2020 Excellent Science - Marie Skłodowska-Curie Actions) 837951European Molecular Biology Organization (EMBO) ALTF 1096-2018Wellcome Trust CC2090Wellcome Trust (Wellcome) 223136/Z/21/Z
6 · The paper itself

Abstract

Type 1 conventional dendritic cells (cDC1s) are key antigen-presenting cells (APCs) for cross-priming of CD8

Indexed as

NeoplasmsReceptors, IgGActinsAnimalsAntigen PresentationAntigens, NeoplasmCD8-Positive T-LymphocytesCell Line, TumorCross-PrimingDendritic CellsHumansLectins, C-TypeMiceMice, Inbred C57BLReceptors, ImmunologicActinsAntigens, NeoplasmClec9a protein, mouseLectins, C-TypeReceptors, IgGReceptors, Immunologic

Identifiers

PMID42162317
PMCPMC13600936

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.